Jackson Creek Investment Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Jackson Creek Investment Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-14,125	Closed	-$1.01M	–	380
2023 Q4	$1.01M	Sell	14,125 -6	-0%	-$345	0.39%	110
2023 Q3	$736K	Sell	14,131 -8	-0.1%	-$466	0.31%	179
2023 Q2	$895K	Buy	+14,139	New	+$881K	0.36%	142
2023 Q1	–	Sell	-16,614	Closed	-$879K	–	378
2022 Q4	$879K	Buy	+16,614	New	+$833K	0.39%	116
2022 Q3	–	Sell	-17,143	Closed	-$928K	–	354
2022 Q2	$928K	Buy	+17,143	New	+$972K	0.38%	140

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jackson Creek Investment Advisors's ITCI Position: Q1 2024 in Review

Jackson Creek Investment Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 14,125 shares — an estimated $1.01M sold.

Jackson Creek Investment Advisors first reported a position in ITCI in Q2 2022 and held it in 5 quarters. The position peaked at $1.01M in Q4 2023. 346 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

Jackson Creek Investment Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
Jackson Creek Investment Advisors sold 14,125 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $1.01M.
Jackson Creek Investment Advisors first reported a position in Intra-Cellular Therapies Inc. in Q2 2022 and held it in 5 quarters.
Jackson Creek Investment Advisors's Intra-Cellular Therapies Inc. position peaked at $1.01M in Q4 2023.
346 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on Jackson Creek Investment Advisors's 13F filing for Q1 2024, filed 10 May 2024.